share_log

Cantor Fitzgerald Reiterates Overweight on Cardiol Therapeutics, Maintains $3 Price Target

Benzinga ·  Aug 14, 2023 08:53

Cantor Fitzgerald analyst Charles Duncan reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Overweight and maintains $3 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment